TOKYO, May 15 (Pulse News Wire) – Medicinova,inc. (4875.T) reported its consolidated financial results for the quarter ending December 2026.
Revenue was $1,262,514 thousand, operating profit was $414,809 thousand, and net income was $252,964 thousand. Research and development expenses amounted to $1,590,175 thousand, while general administrative expenses reached $189,860 thousand. In addition, the company provided updates on its MN-166 clinical trial targeting Amyotrophic Lateral Sclerosis (ALS).
The trial, funded by the National Institutes of Health (NIH) with approximately $10 million, has successfully enrolled 100 patients out of a target of 200 since April last year. The study aims to offer MN-166 to patients ineligible for the ongoing Phase 2b/3 trial (COMBAT-ALS) and collect important biomarker and clinical outcome data. Currently, patient enrollment is underway at 12 facilities.
🟢 Confidence: High AI-translated content.